Trial Profile
Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Therapeutic Use
- Acronyms STIG; STIG-Pompe
- 01 Jul 2021 Results published in the Journal of Neurology
- 05 Feb 2021 Status changed from recruiting to completed.
- 31 Aug 2020 Planned End Date changed from 31 Jul 2020 to 31 Dec 2020.